Sleep Problems and Disorders

When sleep goes wrong, it usually goes wrong in patterns. The system breaks in identifiable ways that medicine has names for, and most of those names point to causes that respond to specific interventions. The popular framing of insomnia as a generic problem to be solved with sleep hygiene tips and possibly a pill misses how much variation exists underneath the surface. Different sleep problems have different mechanisms and different best treatments.

This page covers the clinical territory. What insomnia and sleep apnea actually are, and the circadian rhythm disorders that don’t quite fit either category. We also attempt to look at when sleep medicine has something to offer that you can’t replicate with self-directed practice, where I believe the medical system gets it wrong, where pharmaceutical incentives shape what gets prescribed, and how to be a more informed patient when you do enter the clinical pathway.

The mechanisms behind normal sleep are in Sleep & Circadian Rhythm Basics. The protocols and tools for self-directed sleep improvement are in the Cheat Sheet. What this page does is the part in between: when self-directed approaches aren’t working, when something is genuinely wrong, when a clinical evaluation is the right next step, and what to expect when you take it.

A note before the rest: this page is here to help you navigate the medical system rather than replace it. If sleep is significantly affecting your life, see a clinician. This isn’t a substitute for proper assessment, but there are things you can do to improve your chances of living a healthier life.

The Difference Between Sleep Problems and Sleep Disorders

Most people have occasional sleep problems. Stress before a big event, jet lag, a sick child waking the household, caffeine too late, or a stretch of poor decisions may cause a disturbance. These tend to resolve on their own when the underlying cause goes away. They don’t need medical attention; they need basic adjustments to your environment and behavior. The Cheat Sheet covers the practical tools for these situations.

A sleep disorder is more persistent. Typically defined as occurring at least three nights per week for at least three months in the case of insomnia, or as ongoing patterns for the others. It’s not explained by a temporary cause, it affects daytime function (you’re tired, irritable, cognitively slower, less safe to drive), and it doesn’t resolve reliably.

The clinical distinction matters because the interventions that work for occasional sleep problems often don’t work for genuine sleep disorders, and vice versa. People who try to manage moderate-to-severe sleep apnea with sleep hygiene tips don’t get better, because sleep hygiene isn’t the problem. People who try to treat psychophysiological insomnia with sleep medications often get short-term relief and long-term worsening, because medications don’t address the underlying conditioning that maintains the disorder.

The four major categories

1. Insomnia disorder: difficulty initiating sleep, maintaining sleep, or both, despite adequate opportunity, with daytime consequences
2. Sleep-disordered breathing: primarily obstructive sleep apnea, but also central sleep apnea and upper airway resistance syndrome
3. Circadian rhythm sleep-wake disorders: the SCN-environment misalignment problems
4. Other: narcolepsy, parasomnias (sleepwalking, REM behavior disorder, etc.), restless legs syndrome, and the rest

Insomnia

Insomnia is the most common sleep complaint and the one most often mismanaged. The standard diagnostic criteria require difficulty initiating or maintaining sleep, occurring at least three nights per week, persisting for at least three months, with daytime consequences (fatigue, mood disturbance, cognitive impairment, etc.). Affects roughly 10-15% of adults at any given time and substantially more episodically.

What’s Wrong?

The dominant clinical framework for understanding insomnia is Arthur Spielman’s 3-P model (also called the Spielman model or the predisposing-precipitating-perpetuating model), developed in the 1980s and still the foundation of clinical sleep medicine. It identifies three factors that combine to produce chronic insomnia:

1. Predisposing factors: Underlying tendencies that make someone vulnerable to sleep problems. Genetic predisposition. Anxiety-prone temperament. Higher-than-average baseline arousal. Family history. 
2. Precipitating factors: Acute triggers that cause an initial period of poor sleep. Major life stress. Bereavement. Job loss. Illness. Travel. Most people will have a stretch of poor sleep at some point in their life when one of these arrives. Most people’s sleep recovers on its own.
3. Perpetuating factors: What turns a temporary sleep problem into chronic insomnia. This is the most important category clinically, because it’s where the actual treatment leverage is. The classic perpetuating factors:
   1. Spending more time in bed than you actually sleep. When sleep is bad, the natural response is to go to bed earlier and stay there longer, hoping to catch more sleep. This dilutes sleep efficiency and weakens the bed-sleep association.
   2. Sleep effort. Trying hard to fall asleep activates arousal systems and makes sleep harder. This is one of the cruelest features of insomnia – wanting sleep more makes it harder to come.
   3. Conditioned arousal. The bedroom becomes associated with frustration and not sleeping rather than with sleep. The conditioning operates below conscious awareness.
   4. Catastrophic thinking about sleep loss. Lying awake worrying about how tomorrow will go produces sympathetic activation that maintains the wakefulness.
   5. Compensatory behaviors. Naps, weekend sleep-ins, caffeine to manage daytime fatigue… all of these undermine the sleep pressure (Process S) that should drive nighttime sleep.

By the time someone has chronic insomnia, the original precipitating factor is often long gone. The job stress that triggered the initial poor sleep resolved years ago. What’s maintaining the insomnia now is the perpetuating factors: the conditioning, the effort, the time-in-bed pattern, and the worry. Treating the original stressor doesn’t fix things because the original stressor isn’t the active problem anymore.

This is also why “good sleep hygiene” alone usually doesn’t fix chronic insomnia. Sleep hygiene addresses occasional sleep problems and helps prevent precipitating factors from triggering disorders. It doesn’t address the perpetuating factors that maintain a disorder once it’s established.

The Treatment

Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment for chronic insomnia in essentially every clinical guideline that exists. The American College of Physicians, the American Academy of Sleep Medicine, the European Sleep Research Society, and others all recommend CBT-I before pharmaceutical treatment.

CBT-I is a structured 6–8 week protocol that addresses the perpetuating factors directly. The main components include:

• Sleep restriction therapy: Counterintuitively, the treatment for insomnia often starts with reducing time in bed. If someone is spending 9 hours in bed but only sleeping 6, the protocol restricts them to 6 hours in bed initially. This builds sleep pressure (Process S), consolidates sleep, and rebuilds the bed-sleep association. Time in bed is gradually extended as sleep efficiency improves.
• Stimulus control: Reconditioning the bed and bedroom as cues for sleep. Get out of bed if not asleep within 15-20 minutes. Use the bed only for sleep and sex. Wake up at the same time every day, regardless of how the night went.
• Cognitive therapy: Addressing catastrophic thinking about sleep, the assumption that one bad night ruins the next day, the belief that you need a specific amount of sleep to function. The thoughts contribute to the arousal that maintains insomnia.
• Sleep hygiene: As one component, not the whole treatment.
• Relaxation training: Progressive muscle relaxation, breathing exercises, etc.

Meta-analyses consistently show effect sizes comparable to or larger than those of sleep medications, with benefits that persist after treatment ends rather than disappearing when treatment stops. Charles Morin at Université Laval has been the most influential researcher in this space, with decades of trials demonstrating CBT-I’s effectiveness across populations.

The problem: CBT-I is severely underutilized. Estimates suggest fewer than 10% of insomnia patients in primary care receive CBT-I as first-line treatment, despite it being the recommended first-line treatment. Most receive prescription medications instead. Multiple factors drive this: limited availability of trained CBT-I providers, insurance coverage gaps, patient preference for fast-acting solutions, and time constraints in primary care that favor prescriptions over referrals to multi-week therapy programs.

If you have chronic insomnia, finding access to CBT-I should be a priority over starting medication. Several digital CBT-I programs (Sleepio, CBT-I Coach app from the VA, Somryst) make the protocol more accessible than it used to be. Colin Espie at Oxford developed Sleepio and has been the main researcher on digital CBT-I delivery; the evidence base for digital programs is now strong enough that they’re appropriate first-line options for many patients.

Sleep Medications

Sleep medications are appropriate in some contexts, but they’re inappropriately used in many.

The major classes

• Benzodiazepines (temazepam, lorazepam, etc.): older sleep medications that increase GABA activity. Effective at producing sleep but has significant problems: tolerance develops quickly, withdrawal is unpleasant and potentially serious, cognitive effects (memory, balance), dependence is common, and the sleep produced is architecturally abnormal (heavily sedated). The 2018 American Geriatrics Society Beers Criteria explicitly recommends avoiding benzodiazepines in older adults. Long-term benzodiazepine use is associated with increased dementia risk in observational studies, though causality is contested.
• Z-drugs (zolpidem/Ambien, eszopiclone/Lunesta, zaleplon/Sonata): newer agents marketed as “non-benzodiazepine” though they work through similar GABA mechanisms. Originally promoted as safer than benzodiazepines, subsequent experience has shown the differences are smaller than the marketing suggested. Tolerance, dependence, and complex sleep behaviors (sleep-driving, sleep-eating, occasionally with no memory of the events) all occur. The FDA added a black box warning in 2019 for serious injuries occurring during complex sleep behaviors.
• Orexin receptor antagonists (suvorexant/Belsomra, lemborexant/Dayvigo, daridorexant/Quviviq): newer medications that block the wakefulness-promoting orexin system. The mechanism is more targeted than the GABA-based older drugs. Less abrupt next-day grogginess in trials. Long-term safety is still being characterized. These are the most physiologically interesting sleep medications, working through the actual sleep-wake regulation system rather than general sedation.
• Antihistamines (diphenhydramine/Benadryl/Zzzquil, doxylamine/Unisom): over-the-counter sleep aids. Block histamine, which has wake-promoting effects. Effective for occasional sleeplessness; problematic for chronic use. Anticholinergic side effects accumulate with chronic use, and long-term use of anticholinergic medications (which these are) has been associated with increased dementia risk. These are not appropriate as a long-term insomnia solution.
• Trazodone: an older antidepressant prescribed off-label at low doses for sleep. Used widely despite limited primary research support for the specific application. 

Melatonin

Melatonin is sold over the counter in the US as a supplement (it’s prescription-only in many countries, including Australia, the UK, and most of Europe). The popular framing treats it as a sleep aid; this is mostly wrong about what melatonin actually does.

What melatonin does: It signals biological night to the rest of the system. It’s produced by the pineal gland in response to darkness and tells the body’s various clocks that the dark phase has begun. Its primary role is circadian, not sedative. Endogenous melatonin doesn’t make you sleepy directly so much as enable the conditions for sleepiness.

What melatonin supplementation does well: Modest effectiveness for circadian rhythm disorders, such as jet lag, delayed sleep phase, and shift work. Used appropriately at low doses (0.3–1 mg) at the right circadian time, it can shift the SCN’s phase. Alfred Lewy at Oregon Health & Science University did much of the foundational work on melatonin’s phase-shifting properties.

What melatonin supplementation does poorly: Treating insomnia in people with normal circadian rhythms. The effect on sleep onset is small; the effect on sleep maintenance is essentially nil.

What you should know about commercial melatonin:

The doses sold commercially are dramatically higher than what’s physiologically meaningful. Standard pineal gland production is roughly 0.3 mg over the course of the night. Supplements typically deliver 3-10 mg, and some are sold at 30 mg or higher. The 60-80 mg “for jet lag” recommendation that circulates in some biohacker communities is approximately 200 times the body’s natural production and has no evidence base supporting it. High-dose melatonin can produce paradoxical effects, vivid, disturbing dreams, daytime grogginess, and, at very high doses, hormonal effects (it suppresses gonadotropin-releasing hormone and, at high doses, can suppress reproductive function).

A 2017 Journal of Clinical Sleep Medicine analysis of commercial melatonin products found that actual melatonin content ranged from 17% below to 478% above the labeled amount. Quality control across the supplement industry is genuinely poor.

If you’re going to use melatonin:

• Low doses (0.3-0.5 mg, occasionally up to 1 mg)
• Timed to circadian purpose (e.g., 4-6 hours before desired sleep onset for phase-shifting; not at bedtime for general sleep)
• Short-term use rather than chronic
• For circadian indications (jet lag, shift work, delayed sleep phase) rather than general insomnia
• Pharmaceutical-grade preparations rather than the cheapest commercial supplements

Pre-pubertal children should not take melatonin without specialist supervision; the evidence on developmental effects is limited, and there are theoretical concerns about effects on puberty timing. The concern is contested. Many pediatric sleep specialists do prescribe it, but the framework’s caution-when-evidence-is-thin principle applies.

My general position on melatonin: useful in narrow applications, oversold in popular discourse, and the doses commonly recommended are an order of magnitude higher than what makes physiological sense. Never mess with hormone production if you can help it. 

Sleep Apnea and Sleep-Disordered Breathing

Obstructive sleep apnea (OSA) is one of the most consequential and most underdiagnosed conditions in sleep medicine. The full picture is on the Respiratory Health page; the sleep-specific summary here focuses on what’s relevant for the broader sleep system.

What’s Happening

OSA is a repetitive collapse of the upper airway during sleep. The airway loses muscle tone, narrows or closes entirely, breathing stops or becomes severely restricted, oxygen saturation drops, the brain partially wakes to restore airway tone, breathing resumes, sleep deepens again, and the cycle repeats. Often dozens of times per hour in moderate-to-severe cases.

The mechanism breaks sleep in two ways. First, the brief arousals fragment sleep architecture, particularly preventing sustained N3 deep sleep. Second, the intermittent oxygen desaturation produces oxidative stress and sympathetic nervous system activation that have cardiovascular and metabolic consequences over time.

Underdiagnosis

Estimates suggest roughly a third of adults with moderate-to-severe OSA are undiagnosed. The rate is substantially higher in groups that don’t fit the stereotypical risk profile. Particularly women (where OSA presentations are often subtler and frequently missed) and lean adults (where the assumption that OSA requires obesity leads clinicians to skip evaluation).

The classical signs, such as loud snoring, witnessed pauses, daytime sleepiness, large neck circumference, and BMI in the obese range, catch obvious cases.

They miss many presentations:

• Women may present with insomnia, mood symptoms, fatigue, and morning headaches, more than overt sleepiness
• Lean adults may have OSA driven by craniofacial structure rather than tissue obstruction
• Older adults may present with cognitive complaints attributed to aging
• Children with OSA may present with behavioral problems and ADHD-like symptoms

If sleep is unrefreshing despite adequate duration, if you wake with morning headaches or dry mouth, if your partner reports gasping or pauses, if you have hypertension that’s hard to control, or if you have unexplained chronic fatigue, sleep apnea is worth investigating regardless of whether you fit the stereotypical profile.

Diagnosis and Treatment

Formal diagnosis requires polysomnography (overnight in-lab sleep study) or a validated home sleep test. The home tests have become much more accessible in recent years and are appropriate for many patients, though severe cases or atypical presentations still warrant in-lab studies.

Self-screening tools that suggest formal evaluation:

• STOP-BANG questionnaire: standard clinical screening tool, 8 yes/no questions. Available online.
• Continuous overnight pulse oximetry: consumer devices like Wellue O2Ring or some Garmin/Apple Watch products can capture oxygen desaturation patterns. Repeated drops below 90% during sleep strongly suggest apnea.

Treatment Hierarchy

• CPAP (Continuous Positive Airway Pressure) remains the gold-standard treatment for moderate-to-severe OSA. Pneumatic splinting of the airway prevents collapse. Effective when used consistently. Compliance is the limiting factor. Many patients struggle with the device, particularly the mask fit and the sensation of pressurized air.
• Oral appliances (mandibular advancement devices) are appropriate for mild-to-moderate OSA and for patients who can’t tolerate CPAP. Less effective than CPAP for severe disease, but better than nothing for many.
• Positional therapy for positional OSA. Patients whose apnea is significantly worse on the back. Various devices and tactics to maintain side-sleeping.
• Weight management when obesity is a contributing factor. Effective when achievable; often not the primary issue.
• Surgical options for specific anatomical causes. Adenotonsillectomy in children with hypertrophy, uvulopalatopharyngoplasty in selected adults, maxillomandibular advancement for severe cases.
• Orofacial myofunctional therapy. Emerging adjunct treatment with growing evidence base, particularly in pediatric populations and as a supplement to other treatments.

The CPAP Industry

CPAP works. But the industry around it isn’t without problems worth knowing.

The 2021 Philips DreamStation recall is the most consequential recent event. Polyurethane foam used for sound dampening in millions of CPAP and BiPAP machines could degrade and release potentially carcinogenic compounds into the air patients breathed. The recall affected 5+ million devices and is still working through litigation. Internal documents released through discovery suggest Philips was aware of the foam degradation issue for years before the recall. 

The SAVE trial, published in NEJM in 2016, raised real questions about whether CPAP reduces cardiovascular events in patients with moderate-to-severe OSA who lack daytime sleepiness. The trial enrolled 2,717 patients and found no reduction in cardiovascular events with CPAP versus usual care. This complicates the “everyone with OSA needs CPAP for cardiovascular protection” framing. For symptomatic patients, CPAP improves quality of life and probably does reduce events, but the case for treating asymptomatic OSA on cardiovascular grounds is weaker than the popular discourse suggests.

Circadian Rhythm Disorders

These are the conditions where the SCN’s timing is misaligned with the local environment or the demands placed on it. The mechanisms are different from those of insomnia and sleep apnea, and the treatments are different.

Delayed Sleep-Wake Phase Disorder (DSWPD)

The most common circadian disorder. The person’s circadian rhythm is consistently shifted later than the local schedule allows for. Bedtime is naturally 2 AM or later, wake time is naturally 10 AM or later, and forcing earlier hours produces chronic sleep deprivation rather than adapting the underlying rhythm.

DSWPD is heavily genetic and often presents in adolescence. Roenneberg’s chronotype work has documented that what gets called “extreme night owl” behavior in popular discourse has substantial genetic underpinnings rather than being purely a matter of choice or laziness. About 0.2-10% of the population (depending on diagnostic criteria) meets formal DSWPD criteria.

The standard advice of “just go to bed earlier” doesn’t work because the SCN’s timing isn’t easily forced by behavioral effort alone.

The treatments:

• Bright light therapy in the early morning: directly shifts the SCN earlier through the ipRGC pathway. Typically 30-60 minutes of bright light (5,000+ lux) immediately on waking, gradually moved earlier over weeks.
• Low-dose melatonin in the early evening: taken 4-6 hours before desired sleep onset, also shifts SCN earlier through the phase-response curve. Typically 0.3-0.5 mg, not the higher doses sold commercially.
• Strict consistency: wake time has to be maintained even on weekends; phase advances are easily lost to weekend sleep-ins.
• Avoidance of evening light: particularly important for DSWPD patients, who appear to be more sensitive to phase-delaying effects of evening light than the general population.

For many DSWPD patients, their natural rhythm is shifted in a way that doesn’t fully reset to the standard 9-to-5 schedule even with treatment. Lifestyle adjustments (jobs that allow later start times, partners who tolerate different schedules, recognition that “early to bed, early to rise” isn’t the only valid pattern) sometimes serve people better than treatment that works against their underlying biology.

Advanced Sleep-Wake Phase Disorder (ASWPD)

The opposite: circadian rhythm shifted earlier than desired. Sleep onset at 7 PM, wake time at 3 AM. Less common than DSWPD; more common in older adults as part of normal aging shifts. Treatment uses bright light in the evening (rather than morning) to delay the SCN.

Non-24-Hour Sleep-Wake Rhythm Disorder

Most common in totally blind individuals (without light perception), where the SCN can’t entrain to the day-night cycle and free-runs at its endogenous period of approximately 24.2 hours. The person’s sleep-wake rhythm drifts later by ~12 minutes per day, cycling through normal alignment and complete misalignment over weeks. Tasimelteon (Hetlioz) is FDA-approved for this condition.

Rarely occurs in sighted individuals, but possible.

Shift Work Disorder

Occurs in approximately 10% of shift workers. Chronic misalignment between the body’s circadian rhythm and the schedule the work demands. Long-term shift work has documented health consequences: increased cardiovascular risk, metabolic dysregulation, mental health effects, and the IARC classification of shift work as probably carcinogenic in 2007 was driven partly by these data.

Treatment is partial at best. The underlying mismatch can’t be fully resolved while the work pattern continues.

Strategies include:

• Bright light during the night shift to maintain alertness and shift the SCN
• Strict darkness during daytime sleep (blackout curtains, eye masks)
• Strategic napping
• Melatonin timed appropriately for the inverted schedule
• Recognition that long-term night shift work has health costs that no protocol fully eliminates

For permanent night shift workers, the approach focuses on maximizing what’s possible. For rotating shift workers, the chronic re-adaptation is genuinely hard on the system; consistent shift patterns produce better outcomes than rotating ones.

Jet Lag

Acute circadian misalignment from rapid travel across time zones. The full treatment is in the Cheat Sheet; the summary here:

The body’s circadian system can shift by approximately 1 hour per day under ideal conditions. Crossing 8 time zones eastward produces 8+ days of partial misalignment if the system is left to adjust on its own. Strategic light exposure (bright morning light at the destination, avoidance of evening light), timed melatonin, and consistent meal/exercise patterns at the destination can accelerate adaptation modestly but don’t eliminate the underlying issue.

Eastward travel is harder than westward travel because it requires phase advance (which the system does less easily than phase delay). The “extra” hour going from London to Auckland is metabolically harder than the equivalent westward shift.

Other Sleep Disorders

Narcolepsy

Excessive daytime sleepiness with sudden sleep attacks, often accompanied by cataplexy (sudden loss of muscle tone triggered by emotion), sleep paralysis, and hypnagogic hallucinations. Caused by the loss of orexin/hypocretin neurons in the hypothalamus, characterized in detail by Emmanuel Mignot at Stanford in the late 1990s. Treatment involves stimulants for daytime alertness and sometimes sodium oxybate for nighttime consolidation. Often diagnosed years after symptom onset because the presentation can be subtle.

Restless Legs Syndrome (RLS)

Uncomfortable sensations in the legs at rest, with an urge to move that improves the symptoms. Worsens in the evening and at night. Affects sleep onset and maintenance. Often linked to iron deficiency (ferritin levels, even within “normal” range, many RLS patients improve with iron supplementation when ferritin is below 75 ng/mL). Treatment includes iron repletion when appropriate, dopamine agonists, and gabapentin-class medications for severe cases.

REM Sleep Behavior Disorder (RBD)

Loss of the normal muscle paralysis during REM sleep, causing patients to physically act out their dreams: kicking, punching, sometimes injuring themselves or their bed partners. Important not because it’s common but because it has strong predictive value: RBD precedes the development of Parkinson’s disease, Lewy body dementia, or multiple system atrophy in over 80% of cases, often by years to decades. If you or a partner notice physical movement during dreams (not occasional twitching, but sustained acting out), this warrants neurologic evaluation, both for management of the immediate sleep issue and for the early window into possible neurodegenerative conditions.

Sleepwalking and Other Parasomnias

Behaviors during sleep: sleepwalking, sleep talking, sleep eating, night terrors. Most common in childhood and is usually outgrown. When occurring in adults, often triggered by sleep deprivation, alcohol, or medications. Treatment usually focuses on safety (preventing injury, ensuring environmental safety) and addressing triggers. Z-drugs in particular are known to occasionally produce complex sleep behaviors with no memory.

Industry, Incentives, and Why Sleep Medicine Looks the Way It Does

The pharmaceutical industry around sleep is substantial. The major sleep medication market generates billions in annual revenue. CBT-I, which works at least as well, generates none of this revenue because it’s a structured therapy rather than a billable medication.

This shapes the field in predictable ways. Medications get more research funding than non-pharmacological treatments. Primary care training emphasizes prescribing because that’s what fits in a 12-minute appointment. Sleep speciality training varies in how heavily it emphasizes CBT-I as first-line. Patient awareness of CBT-I as an option remains low because no major commercial entity has an incentive to promote it.

This isn’t a conspiracy. It’s the predictable result of how the medical system’s incentive structures work. The 2021 Annals of Internal Medicine analysis showed that fewer than 10% of insomnia patients receive CBT-I as first-line treatment despite guidelines recommending it as a documentation of the gap.

The CPAP industry has its own version. The Philips DreamStation recall is the cleanest specific case, but the broader pattern of medical device regulation, incentive alignment between manufacturers and sleep clinics, and the difficulty of long-term independent quality assurance all play out in this space.

The implications for patients:

• Ask about CBT-I before accepting a sleep medication: Specifically ask. If your clinician says it’s not available, ask about digital programs (Sleepio, CBT-I Coach, Somryst) or about referral to a behavioral sleep medicine specialist.
• Be sceptical of “just take this pill” framing for chronic insomnia: Acute insomnia (a few weeks during a stressful period) may benefit from short-term medication. Chronic insomnia (months to years) is rarely well-served by long-term medication, regardless of how the prescription is framed.
• Get appropriate evaluation for sleep apnea symptoms: Self-screening tools and consumer pulse oximetry can suggest the need for formal evaluation. Don’t accept “you don’t fit the profile” if your symptoms are consistent with the disorder.
• Understand what your CPAP is and isn’t doing: Treatment compliance, mask fit, pressure settings – these all matter and aren’t always optimized in initial fittings. Advocate for adequate trial periods and adjustments.
• Take supplement claims with appropriate scepticism: The melatonin discussion above applies broadly. The supplement industry has minimal regulatory oversight, marketing claims routinely outrun the evidence, and “natural” doesn’t mean “harmless.”

When to Get Professional Help

The threshold for seeking clinical evaluation:

See a primary care clinician promptly if:

• Sleep problems have persisted for three months or more
• Daytime function is significantly affected (cognition, mood, safety, work)
• You suspect sleep apnea (loud snoring, witnessed apneas, morning headaches, unrefreshing sleep, treatment-resistant hypertension)
• You experience excessive daytime sleepiness despite adequate sleep duration
• A bed partner reports physically acting out dreams
• You have new-onset sleep walking or other parasomnias as an adult
• You have unexplained restless legs or limb movements interfering with sleep
• Sleep problems are accompanied by depression, anxiety, or significant mood changes

Ask specifically for:

• Sleep apnea screening (STOP-BANG or referral for sleep study) if symptoms suggest it
• CBT-I referral or digital program for chronic insomnia (don’t accept a sleep medication prescription as first-line if you haven’t been offered CBT-I)
• Iron studies, including ferritin, if you have restless legs
• Neurologic evaluation for REM behavior disorder

Consider seeing a sleep specialist if:

• Primary care has been unable to address the problem
• You have complex or unusual symptoms
• Initial treatment isn’t working
• You suspect a circadian rhythm disorder
• You have suspected narcolepsy
• You need polysomnography for diagnostic clarity

Behavioral sleep medicine specialists (psychologists trained specifically in sleep) deliver CBT-I and related cognitive behavioral interventions for sleep disorders. The Society of Behavioral Sleep Medicine maintains a directory of qualified providers.

Sleep medicine has gotten substantially better over the last few decades. CBT-I works. Sleep apnea diagnosis is more accessible. Newer medications are more targeted. The system isn’t perfect, but engaging with it is usually better than not engaging when the problem is significant. The framework here is meant to help you be a more informed participant rather than keep you out of the medical system.